Briefing documents released ahead of Wednesday's Pulmonary-Allergy Drugs Advisory Committee pointed to some inconsistent data for Breo (fluticasone furoate/vilanterol), the combination inhaled corticosteroid and long-acting beta2 agonist (LABA) from GlaxoSmithKline plc and Theravance Inc.